(ARGX) Argen-X - Ratings and Ratios
Exchange: BR • Country: Netherlands • Currency: EUR • Type: Common Stock • ISIN: NL0010832176
ARGX: Autoimmune, Therapy, Antibodies, Inflammation, Diseases
Argenx SE, a biotechnology company, is focused on developing innovative therapies for autoimmune diseases. Its lead product candidate, efgartigimod, targets a wide range of conditions, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and others. This drug leverages the companys SIMPLE Antibody Platform, which is known for producing human antibodies that are both potent and have high thermal stability. This platform has attracted significant attention due to its potential to create more effective treatments with fewer side effects.
The companys pipeline is robust, with multiple candidates in various stages of development. For instance, ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis, while ARGX-112 targets immune-mediated conditions. Argenx also has a strategic partnership with AbbVie, Zai Lab, and LEO Pharma, which not only enhances its research capabilities but also provides a strong distribution network across the United States, Japan, Europe, Middle East, Africa, and China.
From a financial standpoint, Argenx has a market capitalization of approximately 39069.32M EUR, with a forward P/E ratio of 96.15. This indicates high expectations for future growth. The companys price-to-book ratio of 9.44 suggests that investors are valuing its assets and future prospects heavily. Argenxs strategic collaborations with academic institutions like the Université Catholique de Louvain and NYU Langone Health underscore its commitment to innovation and its ability to tap into cutting-edge research.
Investors should note that Argenx has a strong intellectual property portfolio, with ownership of several key technologies and trademarks. This includes VYVGART, VYVDURA, and NHANCE, which are crucial for maintaining its competitive edge. The companys partnership with Genmab to develop therapeutic antibodies for immunology and oncology further highlights its strategic approach to diversifying its product offerings and expanding its market reach.
Additional Sources for ARGX Stock
ARGX Stock Overview
| Market Cap in USD | 36,451m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2017-05-18 |
ARGX Stock Ratings
| Growth 5y | 91.5% |
| Fundamental | 32.8% |
| Dividend | 0.0% |
| Rel. Strength | 74.3 |
| Analysts | - |
| Fair Price Momentum | 638.88 EUR |
| Fair Price DCF | - |
ARGX Dividends
No Dividends PaidARGX Growth Ratios
| Growth Correlation 3m | -86.4% |
| Growth Correlation 12m | 91.9% |
| Growth Correlation 5y | 91% |
| CAGR 5y | 33.98% |
| CAGR/Max DD 5y | 0.87 |
| Sharpe Ratio 12m | 1.26 |
| Alpha | 47.42 |
| Beta | 0.196 |
| Volatility | 36.18% |
| Current Volume | 71.8k |
| Average Volume 20d | 91.6k |
As of April 02, 2025, the stock is trading at EUR 543.60 with a total of 71,808 shares traded.
Over the past week, the price has changed by -2.75%, over one month by -9.97%, over three months by -11.00% and over the past year by +50.46%.
Neither. Based on ValueRay Fundamental Analyses, Argen-X is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 32.75 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ARGX as of April 2025 is 638.88. This means that ARGX is currently undervalued and has a potential upside of +17.53% (Margin of Safety).
Argen-X has no consensus analysts rating.
According to ValueRays Forecast Model, ARGX Argen-X will be worth about 692.8 in April 2026. The stock is currently trading at 543.60. This means that the stock has a potential upside of +27.45%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 697.3 | 28.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 692.8 | 27.4% |